Showing 20 of 168 recruiting trials for “Systemic lupus erythematosus”
Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus
👨⚕️ Huaxiang Wu, PhD, Second Affiliated Hospital, School of Medicine, Zhejiang University📍 1 site📅 Started Aug 2024View details ↗
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus
👨⚕️ Qiubai Li, Professor, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology📍 2 sites📅 Started Jul 2024View details ↗
Intervention to Improve Communication and Medication Adherence in Lupus
Integration of Remote Monitoring in the Management of Chronic Immunosuppressive Therapy
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
RecruitingNCT06491602 ↗
A Study of Clinical Characteristics ,Risk Factors and Outcome of Lupus Nephritis Among Children With Systemic Lupus Erthromatousus in Sohag Univeristy Hospital
A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
👨⚕️ Qiubai Li, Professor, Department of Rheumatology and Immunology, Wuhan Union Hospital📍 1 site📅 Started Jun 2024View details ↗
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
👨⚕️ Guillermo J. Valenzuela, M.D., IRIS Research and Development, LLC📍 1 site📅 Started May 2024View details ↗
An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease
Fatigue in Lupus Intervention Programmes (FLIP)
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
👨⚕️ Nan Shen, MD & PhD, Department of Rheumatology, RenJi Hospital, School of Medicine, Shanghai JiaoTong University📍 1 site📅 Started Mar 2024View details ↗
Brief Pain Exposure Therapy (BPET) For Nociplastic Pain
The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
RecruitingNCT06339957 ↗
Rheumatology Diet Study
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →